Dyck

: 2001 ANZJP Zyprexa; New indication, acute mania, bipolar disorder, once-daily dosing, tolerability, mood stabilisation, no induced depression, Make the change. Zyprexa provides efficacy to stabalise mania in patients, with or without psychotic symptoms as early as week 1. Zyprexa does not induce depressive symptoms in bipolar patients with manic or mixed episodes. Zyprexa offers a well-proven safety and tolerability profile. Zyprexa provides simplicity and compliance-building convenience of once-daily dosing. In Bipolar Mania Zyprexa Olanzapine Brining life back in balance., Olanzapine, Eli Lilly Australia Pty. Limited, A man running towards the page on a long concrete road. The whole picture is a hue of purple.

: 2001 ANZJP Zyprexa; Another reason to switch. With the November 1 authority listing change to thioridazine, and the addition of a caution that thioridazine may cause serious arrhythmias, the reasons for re-assessment and switching to Zyprexa are even more compelling now. Not only does Zyprexa effectively tear positive, negative, and depressive symptoms, it does so with no clinically significant Otc prolongation. Switching is simple and with a once-daily starting and therapeutic doe range of 5-20mg, zyprexa encourages compliance and long-term success. Zyprexa Olanzapine Make the change., Olanzapine, Eli Lilly Australia Pty. Limited, A switch with ON/OFF where its resting on ON.

: 2001 APPAL Alplax/Alplax XR; Alplax. Diminishes vulnerability when confronted with stress. Alprazolam. 0.25-0.5-1-2. Alplax. Anxiolytic and anti-depressant from origin. Diminishes vulnerability when confronted with stress. Alprazolam. 0.5-1-1. Alplax. 1 daily dose. XR controlled liberation. Stable comfort anxiolytic and for longer time. Augments comfort and fulfillment., Alprazolam/Alprazolam, Gador, Man walking pictured from behind. Two spheres with people standing around them: one shows a DNA helix, the other is filled with an abstract map of the world.

: 2001 APPAL Elafax XR/Elafax; Venlafaxine. Elafax. 37.5-75-150. XR Controlled Liberation. First mixed inhibitor of the recapture of seratonin and noradrenaline. New symptom. Venlafaxine of controlled liberation is the only antidepressant approved by the FDA in: generalized anxiety disorder (GAD). Venlafaxine. Elafax. 25-50-75. The most effective and safe alternative for the treatment of the depression-anxiety comorbidity. A challenge to the pharmacological limit. They answer., Venlafaxine/Venlafaxine, Gador, Blurred image of an individual riding a bicycle.

: 2001 APPAL Foxetin; Fluoxetine. Foxetin. 10.20. Impulses life. The ISRS of largest worldwide clinical experience in: major depression, dysthymia or depressive neurosis, obsessive compulsive disorder (OCD), in patients of old age, in the long-run treatment of depression, impulse control disorders. Fluoxetine. Foxetin. 10. 20. Demonstrated margin of therapeutic security. Comfortable administration of only one daily dose with better cost/efficacy. New symptom: Premenstrual dysphoric disorder. Fluoxetine: first officially authorized molecule in this symptom., Fluoxetine, Gador, Photograph of a woman and a man walking in the rain. Both look happy. Woman is barefoot and kicking the puddled water.

: 2001 APPAL Hipnodem; Novel and effective treatment of insomnia with maximum flexibility of use. Provides rapid induction. Assures a lucid awakening without effects on memory and psychomotor function. Hipnodem. Zaleplon 5 and 10 mg. To sleep well and wake up alert., Zaleplon, Armstrong Syncro, Photo of a sleeping Mona Lisa.

: 2001 APPAL Irradial; Depression…Irradial. Promotes a positive mood disposition. FDA approved. Sertraline. 50 and 100mg., Sertraline, Armstrong, Sketch of a naked woman who is crouching with her head bent between her arms.

: 2001 APPAL Midax; Midax. Olanzapine. 5*10mg. From the beginning. Change the evolutionary perspectives of your patient. Optimze the prognosis and the evolution. Larger recuperation of cognitive symtpoms as well as negative symptoms. Augments self-esteem. Excellent tolerability and acceptance of treatment. Minimizes the risk of refractoriness., Olanzapine, Gador, Woman walking pictured from behind along with several circles enclosing shaded figures of an individual.

: 2001 APPAL Midax; From the beginning. Midax. 5*10mg. Olanzapine. A better quality of life. Ability for personal care. Return or entry into an economically productive role. Better relationship with family. Augments self-esteem. Changes the evolutionary perspectives of your patient., Olanzapine, Gador, Image of a desert where several men are working to lift different spheres. Walking woman is pictured from behind.

: 2001 APPAL Risperin; Risperin. Risperidone. 1/2/3/4 mg. First ADS antipsychotic. Reintegrates. Betters global cognitive function. Optimizes the use of health resources. Reduces the number of admissions and the time of institutional stays., Risperidone, Gador, Abstract painting of a man who is walking.

: 2001 APPAL Seroquel; Times of change in the treatment of schizophrenia. Beyond control. Seroquel. Quetiapine Fumarate. Atypical antipsychotic. The reason for change., Quetiapine Fumarate, Zeneca/Bago, Photo of a man who is crouching and looks scared.

: 2001 APPAL Somit; Zolpidem 10 mg. Somit. In the dimension of hypnotic clinical selectivity. Zolpidem. Only molecule designed to respect the architecture of sleep and obtain hypnotic clinical selectivity. Zolpidem. The ideal dimension: hypnotic selectivity and quality of sleep that last all night and are reflected on the "next day": alert, awake, recuperated., Zolpidem, Gador, Three different takes of the same individual. Shows the progression of being awake to being asleep. There's also an image of what I think is meant to be a neuroreceptor.

Main menu